<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multi-layer Organotropism: EV Zip-codes + Barrier Gating + Niche Amplification - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-41</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-41</p>
                <p><strong>Name:</strong> Multi-layer Organotropism: EV Zip-codes + Barrier Gating + Niche Amplification</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of preferential metastatic organotropism (non-random metastatic spread to specific organs) across cancers (e.g., prostate/breast to bone, lung to brain/adrenals), based on the following results.</p>
                <p><strong>Description:</strong> Preferential metastatic organotropism emerges from a layered sequence of (1) molecular targeting of small signals (especially extracellular vesicles, EVs) to particular organ-resident recipient cells via surface determinants (e.g., exosomal integrins), (2) organ-specific barrier gating (endothelial permeability, specialized barriers like BBB, and local adhesion/chemokine capture), and (3) local positive-feedback niche amplification (ECM remodeling, stromal transdifferentiation, immune suppression, and metabolic resource reallocation). The same primary tumor can therefore exhibit organ-specific metastasis patterns because different organs provide distinct "first responder" cell types (AEC II in lung, Kupffer cells/LSECs/HSCs in liver, BMECs/astrocytes/microglia in brain, osteoblast/osteoclast-lineage and marrow immune cells in bone) that transform systemic EV cues into organ-local chemokines, barrier changes, and supportive niches that increase seeding probability and post-seeding fitness.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5.2-2025-12-11</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: EV organ-targeting is determined by surface 'zip-codes' and recipient-cell identity</h3>
            <p><strong>Statement:</strong> If tumor-derived EVs express specific surface determinants (notably integrin heterodimers), then they preferentially accumulate in and are internalized by specific organ-resident recipient cells; this organ- and cell-selective uptake initiates organ-specific transcriptional and phenotypic programs that bias subsequent metastatic seeding toward that organ.</p>
            <p><strong>Domain/Scope:</strong> Solid-tumor and melanoma models where EV biodistribution and uptake are measured after systemic delivery; applies to lung/liver/brain organotropism claims explicitly tied to exosomal integrins and recipient-cell uptake; does not assert EVs are the sole determinant of organotropism.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Recipient-cell targeting can be overridden by alternative delivery routes (e.g., intraventricular vs systemic brain delivery changes the primary recipient and downstream response).</li>
                <li>High-flow/first-pass organs (lung, liver) may show partial non-specific EV exposure; organotropism requires differential uptake/response rather than mere exposure.</li>
                <li>EV heterogeneity and isolation methods can blur which EV subtype carries the functional 'zip-code'.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Exosomal integrin profiles correlate with organ tropism: α6β4/α6β1 with lung, αvβ5 with liver; integrin patterns are described as determining organ-specific uptake and PMN formation. <a href="../results/extraction-result-158.html#e158.5" class="evidence-link">[e158.5]</a> <a href="../results/extraction-result-165.html#e165.0" class="evidence-link">[e165.0]</a> <a href="../results/extraction-result-163.html#e163.0" class="evidence-link">[e163.0]</a> <a href="../results/extraction-result-160.html#e160.4" class="evidence-link">[e160.4]</a> <a href="../results/extraction-result-162.html#e162.0" class="evidence-link">[e162.0]</a> <a href="../results/extraction-result-159.html#e159.0" class="evidence-link">[e159.0]</a> </li>
    <li>Melanoma-derived exosomes preferentially localize to lung, spleen, bone marrow and liver after IV injection, aligning with common metastatic sites. <a href="../results/extraction-result-165.html#e165.1" class="evidence-link">[e165.1]</a> </li>
    <li>Breast tumor exosomes localize predominantly to SP-C+ AEC II in lung in vivo, identifying an organ-specific parenchymal recipient cell type. <a href="../results/extraction-result-219.html#e219.2" class="evidence-link">[e219.2]</a> <a href="../results/extraction-result-219.html#e219.0" class="evidence-link">[e219.0]</a> </li>
    <li>PDAC exosomes preferentially accumulate in liver and are taken up mainly by Kupffer cells (>80% of exosome+ liver cells are F4/80+ in the cited work), indicating recipient-cell specificity within the organ. <a href="../results/extraction-result-217.html#e217.0" class="evidence-link">[e217.0]</a> <a href="../results/extraction-result-163.html#e163.1" class="evidence-link">[e163.1]</a> <a href="../results/extraction-result-160.html#e160.0" class="evidence-link">[e160.0]</a> </li>
    <li>Lung cancer exosomes are captured by brain endothelium after systemic injection (localized around CD31+ vessels), indicating organ-specific endothelial recipient uptake at the BBB interface. <a href="../results/extraction-result-157.html#e157.0" class="evidence-link">[e157.0]</a> <a href="../results/extraction-result-157.html#e157.1" class="evidence-link">[e157.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Builds directly on established integrin-zip-code work but synthesizes it into a cross-organ layered mechanism that links targeting to barrier changes and niche amplification, providing broader predictive structure.</p>            <p><strong>What Already Exists:</strong> The exosomal integrin 'zip-code' concept and organ-resident EV uptake as drivers of PMN have substantial precedent (e.g., Hoshino et al.).</p>            <p><strong>What is Novel:</strong> The explicit unification of integrin-guided EV targeting with downstream barrier gating and local positive-feedback niche amplification as a single layered causal chain across lung/liver/brain/bone/peritoneum, emphasizing 'first responder' recipient-cell identity as the main organ-specific decision point.</p>
        <p><strong>References:</strong> <ul>
    <li>Hoshino (2015/2016) Tumour exosome integrins determine organotropic metastasis [integrin zip-code mechanism; EV organotropism]</li>
    <li>Costa-Silva (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver [recipient-cell specificity; KC→TGFβ→HSC→FN cascade]</li>
    <li>Fong (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche [metabolic niche priming]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Barrier gating and vascular remodeling are necessary for brain and enhance lung/liver seeding</h3>
            <p><strong>Statement:</strong> If organ endothelium is reprogrammed toward higher permeability and pro-adhesive/inflammatory states (via EV miRNAs/proteins or inflammation-induced selectins), then circulating tumor cells have increased probability of arrest and extravasation; this effect is organ-dependent, being essential for BBB crossing in brain and modulatory (but still impactful) in lung and liver microvasculature.</p>
            <p><strong>Domain/Scope:</strong> Metastasis steps involving vascular arrest/extravasation in brain/lung/liver as modeled in microfluidic BBB systems, in vivo EV education studies, and EV/endothelial mechanistic studies; excludes non-hematogenous routes such as peritoneal implantation.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Endothelial permeability alone does not fully predict extravasation frequency; chemokines and mechanics also contribute.</li>
                <li>BBB disruption mechanisms can depend on whether EVs interact with BMECs (systemic route) versus direct parenchymal exposure (bypassing BBB).</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Breast cancer exosomal miR-105 disrupts endothelial tight junction ZO-1, increasing vascular permeability and promoting metastasis (lung/brain endothelia). <a href="../results/extraction-result-163.html#e163.5" class="evidence-link">[e163.5]</a> <a href="../results/extraction-result-158.html#e158.3" class="evidence-link">[e158.3]</a> <a href="../results/extraction-result-160.html#e160.2" class="evidence-link">[e160.2]</a> <a href="../results/extraction-result-165.html#e165.4" class="evidence-link">[e165.4]</a> </li>
    <li>Breast cancer EVs (multiple miRNAs including miR-181c/miR-105) disrupt BBB integrity; BBB models show tumor extravasation dynamics and astrocyte/endothelial mediators (MMPs, COX-2, gap junction signaling). <a href="../results/extraction-result-160.html#e160.2" class="evidence-link">[e160.2]</a> <a href="../results/extraction-result-164.html#e164.4" class="evidence-link">[e164.4]</a> <a href="../results/extraction-result-165.html#e165.4" class="evidence-link">[e165.4]</a> </li>
    <li>Gastric cancer EVs disrupt endothelial integrity via a dynamin-dependent pathway, increasing vascular leakage and transendothelial migration promoting lung metastasis in mice. <a href="../results/extraction-result-159.html#e159.3" class="evidence-link">[e159.3]</a> </li>
    <li>Review evidence for adhesion/extravasation cascade: selectins/integrins/ICAM-VCAM/chemokines; hypoxia increases extravasation 1.5–3.5× and β1 integrin knockdown reduces stable protrusions/extravasation. <a href="../results/extraction-result-164.html#e164.0" class="evidence-link">[e164.0]</a> </li>
    <li>Lung inflammation upregulates E-selectin and increases metastasis; microfluidic lung models show CXCL12-driven extravasation and AMD3100 reduces colony area. <a href="../results/extraction-result-164.html#e164.3" class="evidence-link">[e164.3]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Integrates known mechanisms into an organ-conditional statement with explicit scope and predictive intervention prioritization by organ barrier type.</p>            <p><strong>What Already Exists:</strong> BBB disruption and vascular permeability mechanisms in metastasis are well established; adhesion cascade is classic.</p>            <p><strong>What is Novel:</strong> Frames barrier gating as a required 'organ-specific gate' for brain but a tunable amplifier for lung/liver, allowing predictions about which interventions (permeability vs chemokine vs ECM) will be organ-selective.</p>
        <p><strong>References:</strong> <ul>
    <li>Zhou (2014) Cancer-secreted miR-105 destroys vascular endothelial barriers [endothelial barrier disruption]</li>
    <li>Valiente/Chen et al. brain metastasis niche literature [astrocyte/microglia support, gap junction signaling]</li>
    <li>Microfluidic metastasis models (various, 2021 reviews) [organ-specific barrier modeling]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Local niche amplification via immune recruitment/phenotype switching creates organ-specific 'soil'</h3>
            <p><strong>Statement:</strong> If EV-educated or inflammation-educated organ-resident cells upregulate chemokines/cytokines (e.g., CCL2, CXCL5, CXCL12, Ptgs2/TNF/Ccl/Cxcl panels) or immunoregulatory mediators (e.g., Dkk-1, PD-L1 induction), then myeloid cells are recruited or reprogrammed (MDSCs, macrophages, microglia), producing an immunosuppressive and pro-remodeling niche that amplifies organ-specific metastatic colonization probability.</p>
            <p><strong>Domain/Scope:</strong> Pre-metastatic niche formation contexts across lung/liver/brain/bone where cytokine induction and myeloid recruitment/reprogramming are demonstrated; applies to both tumor-derived EV and host-derived EV mechanisms.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Immune pathways can be route-dependent (systemic vs local exposure in brain).</li>
                <li>A given cytokine may be elevated but non-essential in a specific model (e.g., IL-17F in 4T1 bone osteolysis).</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Breast exosomal miR-200b-3p induces lung epithelial CCL2; CCL2 recruits CCR2+ myeloid cells/MDSCs; CCL2 knockout reduces lung MDSCs and metastasis; lung-specific CCL2 overexpression increases lung metastasis. <a href="../results/extraction-result-219.html#e219.0" class="evidence-link">[e219.0]</a> <a href="../results/extraction-result-219.html#e219.1" class="evidence-link">[e219.1]</a> <a href="../results/extraction-result-219.html#e219.2" class="evidence-link">[e219.2]</a> <a href="../results/extraction-result-219.html#e219.3" class="evidence-link">[e219.3]</a> <a href="../results/extraction-result-219.html#e219.4" class="evidence-link">[e219.4]</a> <a href="../results/extraction-result-158.html#e158.6" class="evidence-link">[e158.6]</a> </li>
    <li>Lung cancer exosomes induce BMEC Dkk-1 which suppresses microglial activation and biases microglia to M2-like phenotypes; Dkk-1 knockdown prevents this; AMPK phosphorylation correlates with M1→M2 conversion. <a href="../results/extraction-result-157.html#e157.0" class="evidence-link">[e157.0]</a> <a href="../results/extraction-result-157.html#e157.1" class="evidence-link">[e157.1]</a> <a href="../results/extraction-result-157.html#e157.2" class="evidence-link">[e157.2]</a> </li>
    <li>CEMIP+ tumor exosomes induce a pro-inflammatory vascular niche in brain (Ptgs2, TNF, Ccl/Cxcl upregulation) in brain endothelial/microglial cells and associate with brain metastasis progression. <a href="../results/extraction-result-163.html#e163.3" class="evidence-link">[e163.3]</a> <a href="../results/extraction-result-162.html#e162.3" class="evidence-link">[e162.3]</a> </li>
    <li>CRC exosomal miR-934 drives macrophage M2 polarization via PTEN/PI3K/AKT, generating CXCL13/CXCR5 feedback that promotes liver PMN and metastasis. <a href="../results/extraction-result-163.html#e163.10" class="evidence-link">[e163.10]</a> </li>
    <li>GC exosomal miR-92a-3p activates ERK in lung macrophages, upregulates PD-L1 and promotes lung colonization; ERK inhibitor reduces PD-L1 and colonization. <a href="../results/extraction-result-159.html#e159.2" class="evidence-link">[e159.2]</a> </li>
    <li>General EV-mediated immune suppression pathways across organs (TLR/MyD88→IL-6/TNF→MDSCs; exosomal PD-L1; Hsp72-TLR2-STAT3/ERK MDSC activation) are described as PMN features. <a href="../results/extraction-result-165.html#e165.7" class="evidence-link">[e165.7]</a> <a href="../results/extraction-result-160.html#e160.5" class="evidence-link">[e160.5]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Synthesis-level novelty; mechanistic elements exist, but the modular decomposition (targeting→barrier→immune amplification) yields new cross-organ predictions.</p>            <p><strong>What Already Exists:</strong> Immune recruitment/reprogramming as a PMN hallmark is well established across many cancers.</p>            <p><strong>What is Novel:</strong> Explicitly treats immune reprogramming as an amplification module downstream of organ-specific 'first responder' recipient cells, which helps explain why distinct organs converge on similar immune-suppressive endpoints via different upstream EV-recipient interactions.</p>
        <p><strong>References:</strong> <ul>
    <li>Kaplan (2005) VEGFR1+ HPCs initiate the pre-metastatic niche [BMDC recruitment framework]</li>
    <li>Costa-Silva (2015) PDAC exosomal MIF primes liver [KC/HSC/myeloid recruitment]</li>
    <li>Multiple EV-PMN immune modulation reviews (2019–2024) [broad immune suppression via EVs]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: ECM/mechanics and metabolic priming are organ-selective niche stabilizers</h3>
            <p><strong>Statement:</strong> If EVs or organ-resident stromal cells remodel ECM composition/stiffness or reallocate metabolic resources (e.g., fibronectin deposition, osteolysis, reduced glucose uptake by niche cells), then post-extravasation survival/colonization is increased, and organotropism is strengthened toward organs where such remodeling is efficiently induced (liver fibrosis-like FN deposition, lung mechanics changes, bone osteolytic niche, brain metabolic support).</p>
            <p><strong>Domain/Scope:</strong> Preclinical models and organ-on-chip systems demonstrating EV-driven ECM/mechanical/metabolic changes in lung, liver, bone, brain; not intended to cover all metabolic routes or all cancers.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some ECM or cytokine changes can be permissive but not sufficient without immune or barrier changes.</li>
                <li>Bone remodeling can yield divergent lesion phenotypes (osteolytic vs osteoblastic) depending on tumor EV cargo (e.g., PLD/AREG/miRNAs).</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>PDAC exosomal MIF triggers KC TGFβ secretion → HSC activation → fibronectin deposition; conditional fibronectin knockout or CD11b+ cell depletion abrogates exosome-driven liver metastasis amplification. <a href="../results/extraction-result-217.html#e217.0" class="evidence-link">[e217.0]</a> <a href="../results/extraction-result-165.html#e165.2" class="evidence-link">[e165.2]</a> <a href="../results/extraction-result-160.html#e160.0" class="evidence-link">[e160.0]</a> </li>
    <li>Breast cancer EVs in a human liver-chip induce LSEC activation/EndMT and fibronectin upregulation via EV-carried TGFβ1; liver tropism mediated by CXCL12 gradients in tissue-slice models. <a href="../results/extraction-result-164.html#e164.2" class="evidence-link">[e164.2]</a> </li>
    <li>Breast cancer EV miR-122 reduces PKM2/GLUT1 and glucose uptake in lung fibroblasts and brain astrocytes, increasing nutrient availability for tumor cells and promoting metastasis. <a href="../results/extraction-result-163.html#e163.4" class="evidence-link">[e163.4]</a> <a href="../results/extraction-result-165.html#e165.3" class="evidence-link">[e165.3]</a> <a href="../results/extraction-result-158.html#e158.3" class="evidence-link">[e158.3]</a> <a href="../results/extraction-result-160.html#e160.2" class="evidence-link">[e160.2]</a> </li>
    <li>Breast cancer EVs can modify lung mechanics through fibroblast/ECM reprogramming (stiffness/elasticity changes) associated with permissive lung colonization. <a href="../results/extraction-result-162.html#e162.6" class="evidence-link">[e162.6]</a> </li>
    <li>Bone PMN: tumor/exosomal signals (e.g., miR-21; AREG; PLD; multiple miRNAs/lncRNAs) shift osteoclast/osteoblast balance; immune RANKL+ T cells induce osteolysis before tumor arrival; systemic OPG/RANKL ratio drops 10–20× in metastatic 4T1 model. <a href="../results/extraction-result-158.html#e158.1" class="evidence-link">[e158.1]</a> <a href="../results/extraction-result-160.html#e160.3" class="evidence-link">[e160.3]</a> <a href="../results/extraction-result-218.html#e218.0" class="evidence-link">[e218.0]</a> <a href="../results/extraction-result-218.html#e218.2" class="evidence-link">[e218.2]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Conceptual synthesis rather than discovery of a new molecule; nonetheless provides a more predictive, modular causal organization across organ sites.</p>            <p><strong>What Already Exists:</strong> ECM remodeling and metabolic priming in PMNs are established concepts (fibronectin deposition; metabolic reprogramming via miR-122).</p>            <p><strong>What is Novel:</strong> Treats ECM/mechanics/metabolic priming as 'stabilizer' modules that explain persistence/dormancy vs outgrowth differences across organs, and predicts intervention sensitivity differences (e.g., stiffness modulation in liver-chip dormancy).</p>
        <p><strong>References:</strong> <ul>
    <li>Fong (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism [metabolic PMN priming]</li>
    <li>Kaplan (2005) fibronectin-mediated BMDC clustering [ECM as niche scaffold]</li>
    <li>Bone metastasis EV and RANKL literature [osteolytic/osteoblastic niche control]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Blocking EV uptake specifically in the organ's dominant 'first responder' cell type (AEC II in lung; Kupffer/LSEC in liver; BMEC in brain) will reduce subsequent metastasis more effectively than globally reducing endothelial permeability alone, but only for the corresponding organ.</li>
                <li>In models where exosomal miR-105 (or CRC miR-25-3p) is abundant, tight-junction protein levels (ZO-1/occludin/claudin5) will decrease in recipient organ endothelium before detectable tumor cells arrive, and permeability assays will correlate with later metastasis burden.</li>
                <li>In liver PMN models driven by fibronectin deposition (PDAC MIF; BC EV-TGFβ1), myeloid recruitment markers (F4/80+ macrophages) will scale with fibronectin area fraction and predict later metastatic burden.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Engineering exosomes to display a non-native integrin 'zip-code' (e.g., αvβ5 on otherwise lung-tropic EVs) will retarget EV uptake and partially retarget metastasis only if the new organ also provides compatible barrier gating signals (e.g., permissive sinusoidal endothelium), implying a necessary AND gate (zip-code AND barrier permissiveness).</li>
                <li>In brain models, selectively preventing BMEC secretion of Dkk-1 will shift the brain immune niche toward M1-like microglia and reduce brain colonization even without changing BBB permeability; this would separate immune gating from physical gating.</li>
                <li>Mechanical loading/exercise-like osteocyte stimulation (PGE2-mediated barrier reinforcement) could synergize with chemokine blockade (e.g., CXCL5-CXCR2) to suppress bone extravasation more than either alone.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If EV integrin profiles are experimentally altered but EV biodistribution and organ PMN readouts do not change, then the 'zip-code' layer would be insufficient to explain targeting in that model.</li>
                <li>If BBB disruption markers (tight junction loss, permeability) are not required for brain metastasis in a given brain-tropic line, then barrier gating is not a necessary layer for that context.</li>
                <li>If immune suppression in the target organ is experimentally prevented (e.g., myeloid depletion or PD-L1 blockade) but metastasis proceeds unchanged, then immune amplification is not causal in that organ/context.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Fusion-hybrid-mediated organotropism (tumor–myeloid cell hybrids) provides an EV-independent route to organ-selective trafficking and is not fully reduced to EV layers in this general theory. <a href="../results/extraction-result-161.html#e161.0" class="evidence-link">[e161.0]</a> <a href="../results/extraction-result-161.html#e161.1" class="evidence-link">[e161.1]</a> <a href="../results/extraction-result-161.html#e161.2" class="evidence-link">[e161.2]</a> <a href="../results/extraction-result-161.html#e161.3" class="evidence-link">[e161.3]</a> <a href="../results/extraction-result-161.html#e161.5" class="evidence-link">[e161.5]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>